Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Mortality from 1994 to 1 January 2015 in patients with rheumatoid arthritis who received alemtuzumab between 1991 and 1994

From: Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies

  Number of patients Primary cause of death
All deaths 37  
Cardiovascular and atherosclerotic disease 12 Ischaemic heart disease (n = 8), respiratory compromise secondary to heart failure (n = 1), multi infarct dementia (n = 1), bowel infarction secondary to atrial fibrillation (n = 1), superior mesenteric artery infarction (n = 1)
Infection 11 Respiratory (n = 10), renal tract (n = 1)
Malignancy 8 Lung primary (n = 3), non-Hodgkin’s lymphoma (n = 1), breast primary (n = 1), brain tumour (n = 1), stomach leiomyosarcoma (n = 1), unknown primary (n = 1)
Other 6 Non-malignant gastrointestinal tract perforation (n = 2), pulmonary fibrosis (n = 1), dementia (n = 1), upper gastrointestinal bleed (n = 1), primary sclerosing cholangitis (n = 1)